Advantage Alpha Capital Partners LP Has $107,000 Stock Holdings in Gyre Therapeutics, Inc. (NASDAQ:GYRE)

Advantage Alpha Capital Partners LP reduced its position in shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) by 66.7% during the fourth quarter, Holdings Channel reports. The institutional investor owned 8,873 shares of the company’s stock after selling 17,761 shares during the period. Advantage Alpha Capital Partners LP’s holdings in Gyre Therapeutics were worth $107,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in GYRE. FMR LLC bought a new stake in shares of Gyre Therapeutics during the third quarter valued at approximately $47,000. Barclays PLC increased its stake in Gyre Therapeutics by 281.8% during the 3rd quarter. Barclays PLC now owns 9,288 shares of the company’s stock valued at $116,000 after purchasing an additional 6,855 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in Gyre Therapeutics by 11.1% during the fourth quarter. Bank of New York Mellon Corp now owns 13,896 shares of the company’s stock worth $168,000 after buying an additional 1,389 shares during the last quarter. SBI Securities Co. Ltd. bought a new position in shares of Gyre Therapeutics in the fourth quarter valued at $1,225,000. Finally, State Street Corp grew its holdings in shares of Gyre Therapeutics by 8.8% during the third quarter. State Street Corp now owns 104,490 shares of the company’s stock valued at $1,310,000 after buying an additional 8,412 shares during the last quarter. Institutional investors own 23.99% of the company’s stock.

Analysts Set New Price Targets

Separately, Noble Financial began coverage on shares of Gyre Therapeutics in a report on Tuesday, March 11th. They issued an “outperform” rating on the stock.

Gyre Therapeutics Stock Down 5.1 %

GYRE stock opened at $9.21 on Tuesday. The firm has a market capitalization of $862.17 million, a PE ratio of 184.20 and a beta of 1.93. Gyre Therapeutics, Inc. has a twelve month low of $8.26 and a twelve month high of $19.00. The stock’s 50 day moving average is $11.29 and its 200-day moving average is $12.18.

Gyre Therapeutics (NASDAQ:GYRE) last posted its quarterly earnings data on Monday, March 17th. The company reported $0.01 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.03). The firm had revenue of $27.87 million for the quarter, compared to analysts’ expectations of $23.50 million. Gyre Therapeutics had a negative return on equity of 118.43% and a negative net margin of 84.57%.

Insiders Place Their Bets

In other news, President Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock in a transaction on Thursday, December 26th. The stock was sold at an average price of $12.70, for a total transaction of $25,400.00. Following the sale, the president now directly owns 2,928,467 shares in the company, valued at $37,191,530.90. The trade was a 0.07 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last quarter, insiders have sold 36,054 shares of company stock valued at $407,317. Insiders own 19.52% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.